Amyris, Inc. (AMRS) ist ein börsennotiertes Unternehmen im Grundstoffe Sektor, tätig in der Chemicals - Specialty Branche. Der Hauptsitz des Unternehmens ist in EmeryVille, CA, United States. Der aktuelle CEO ist Hermanus Kieftenbeld.
AMRS hat IPO-Datum 2010-09-28, 1,598 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select.
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty, and flavors and fragrance markets in Europe, North America, Asia, and South America. The company manufactures and sells clean beauty, personal care, and health and wellness consumer products, as well as ingredients to the flavor and fragrance, nutrition, food and beverage, and clean beauty and personal care end markets. It offers its products under the Biossance, Pipette, Purecane, Terasana, Costa Brazil, OLIKA, Rose Inc., and JVN brand names. The company has a collaboration agreement with the Infectious Disease Research Institute for the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
